הנחיות האיגוד הישראלי להמטולוגיה ואונקולוגיה ילדים 2014
- The thalassemia syndromes are a heterogeneous group of disorders characterized by variable degrees of hemolysis, chronic anemia, and ineffective erythropoiesis.
- Because more patients are living longer, disease- and treatment-related complications are becoming more common.
- Optimal and safe transfusion support, iron chelation, noninvasive iron assessments, and stem cell therapies provide new tools for effective management of thalassemia.
Pediatr Clin N Am 60 (2013) 1383–1391 http://dx.doi.org/10.1016/j.pcl.2013.08.008
Patients with b-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years.
BLOOD, 1 NOVEMBER 2012 | VOLUME 120, NUMBER 18
The purpose of this article is to set forth our approach to diagnosing and managing the
thalassemias, including b-thalassemia intermedia and b-thalassemia major.
BLOOD, 29 SEPTEMBER 2011 | VOLUME 118, NUMBER 13
British Journal of Haematology, 149, 35–49, doi:10.1111/j.1365-2141.2009.08054.x